Kurs
+1,34%
Likviditet
3 887 MSEK
Kalender
| Tid* | ||
| 2025-04-29 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-06 | 08:00 | Bokslutskommuniké 2024 |
| 2024-11-12 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-08 | - | X-dag halvårsutdelning AZN 77.600002 |
| 2024-07-25 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-25 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-11 | - | Årsstämma |
| 2024-02-22 | - | X-dag halvårsutdelning AZN 20.65 |
| 2024-02-08 | - | Bokslutskommuniké 2023 |
| 2023-11-09 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-10 | - | X-dag halvårsutdelning AZN 9.64 |
| 2023-07-28 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-27 | - | Årsstämma |
| 2023-04-27 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-23 | - | X-dag halvårsutdelning AZN 20.69 |
| 2023-02-09 | - | Bokslutskommuniké 2022 |
| 2022-11-10 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-11 | - | X-dag halvårsutdelning AZN 9.49 |
| 2022-07-29 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-29 | - | Årsstämma |
| 2022-04-29 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | - | X-dag halvårsutdelning AZN 1.97 |
| 2022-02-10 | - | Bokslutskommuniké 2021 |
| 2021-11-12 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-12 | - | X-dag halvårsutdelning AZN 7.72 |
| 2021-07-29 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-11 | - | Årsstämma |
| 2021-04-30 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-25 | - | X-dag halvårsutdelning AZN 15.76 |
| 2021-02-11 | - | Bokslutskommuniké 2020 |
| 2020-11-05 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-13 | - | X-dag halvårsutdelning AZN 7.87 |
| 2020-07-30 | - | Kvartalsrapport 2020-Q2 |
| 2020-04-29 | - | Årsstämma |
| 2020-04-29 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-27 | - | X-dag halvårsutdelning AZN 18.32 |
| 2020-02-14 | - | Bokslutskommuniké 2019 |
| 2019-10-24 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-08 | - | X-dag halvårsutdelning AZN 8.49 |
| 2019-07-25 | - | Kvartalsrapport 2019-Q2 |
| 2019-04-26 | - | Årsstämma |
| 2019-04-26 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-28 | - | X-dag halvårsutdelning AZN 17.46 |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-11-08 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-09 | - | X-dag halvårsutdelning AZN 7.92 |
| 2018-07-26 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-18 | - | Årsstämma |
| 2018-05-18 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-15 | - | X-dag halvårsutdelning AZN 14.97 |
| 2018-02-02 | - | Bokslutskommuniké 2017 |
| 2017-11-09 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-10 | - | X-dag halvårsutdelning AZN 7.4 |
| 2017-07-27 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-27 | - | Årsstämma |
| 2017-04-27 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-16 | - | X-dag halvårsutdelning AZN 16.57 |
| 2017-02-02 | - | Bokslutskommuniké 2016 |
| 2016-11-10 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-11 | - | X-dag halvårsutdelning AZN 7.81 |
| 2016-07-28 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-29 | - | Årsstämma |
| 2016-04-29 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-18 | - | X-dag halvårsutdelning AZN 16.26 |
| 2016-02-04 | - | Bokslutskommuniké 2015 |
| 2015-11-05 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-13 | - | X-dag halvårsutdelning AZN 7.71 |
| 2015-07-30 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-24 | - | Årsstämma |
| 2015-04-24 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-19 | - | X-dag halvårsutdelning AZN 15.62 |
| 2015-02-05 | - | Bokslutskommuniké 2014 |
| 2014-11-06 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-13 | - | X-dag halvårsutdelning AZN 6.2 |
| 2014-07-31 | - | Kvartalsrapport 2014-Q2 |
| 2014-04-24 | - | Årsstämma |
| 2014-04-24 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-19 | - | X-dag halvårsutdelning AZN 129.777777 |
| 2014-02-06 | - | Bokslutskommuniké 2013 |
| 2013-10-31 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-14 | - | X-dag halvårsutdelning AZN 65.777779 |
| 2013-08-01 | - | Kvartalsrapport 2013-Q2 |
| 2013-08-01 | - | Analytiker möte 2013 |
| 2013-04-25 | - | Årsstämma |
| 2013-04-25 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-13 | - | X-dag halvårsutdelning AZN 133.888888 |
| 2013-01-31 | - | Bokslutskommuniké 2012 |
| 2012-10-25 | - | Kvartalsrapport 2012-Q3 |
| 2012-10-25 | - | Analytiker möte 2012 |
| 2012-08-08 | - | X-dag halvårsutdelning AZN 64.555556 |
| 2012-07-26 | - | Kvartalsrapport 2012-Q2 |
| 2012-04-26 | - | Årsstämma |
| 2012-04-26 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-15 | - | X-dag halvårsutdelning AZN 137.333333 |
| 2012-02-02 | - | Bokslutskommuniké 2011 |
| 2011-10-27 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-03 | - | X-dag halvårsutdelning AZN 57.666665 |
| 2011-07-28 | - | Kvartalsrapport 2011-Q2 |
| 2011-04-28 | - | Årsstämma |
| 2011-04-28 | - | Kvartalsrapport 2011-Q1 |
| 2011-02-02 | - | X-dag halvårsutdelning AZN 129.666662 |
| 2011-01-27 | - | Bokslutskommuniké 2010 |
| 2010-10-28 | - | Kvartalsrapport 2010-Q3 |
| 2010-08-04 | - | X-dag halvårsutdelning AZN 5.12 |
| 2010-07-29 | - | Kvartalsrapport 2010-Q2 |
| 2010-04-29 | - | Kvartalsrapport 2010-Q1 |
| 2010-02-03 | - | X-dag halvårsutdelning AZN 12.43 |
| 2010-01-28 | - | Bokslutskommuniké 2009 |
| 2009-10-29 | - | Kvartalsrapport 2009-Q3 |
| 2009-08-05 | - | X-dag halvårsutdelning AZN 4.41 |
| 2009-07-30 | - | Kvartalsrapport 2009-Q2 |
| 2009-04-30 | - | Årsstämma |
| 2009-04-30 | - | Kvartalsrapport 2009-Q1 |
| 2009-02-04 | - | X-dag halvårsutdelning AZN 12.02 |
| 2008-08-06 | - | X-dag halvårsutdelning AZN 3.34 |
| 2008-02-06 | - | X-dag halvårsutdelning AZN 8.61 |
| 2007-08-08 | - | X-dag halvårsutdelning AZN 3.49 |
| 2007-02-07 | - | X-dag halvårsutdelning AZN 8.6 |
| 2006-08-09 | - | X-dag halvårsutdelning AZN 3.6 |
| 2006-02-08 | - | X-dag halvårsutdelning AZN 7.02 |
| 2005-08-10 | - | X-dag halvårsutdelning AZN 2.99 |
| 2005-02-09 | - | X-dag halvårsutdelning AZN 4.497 |
| 2004-08-11 | - | X-dag halvårsutdelning AZN 2.2 |
| 2004-02-18 | - | X-dag halvårsutdelning AZN 3.91 |
| 2003-08-20 | - | X-dag halvårsutdelning AZN 2.07 |
| 2003-02-19 | - | X-dag halvårsutdelning AZN 3.99 |
| 2002-08-21 | - | X-dag halvårsutdelning AZN 2.21 |
| 2002-02-20 | - | X-dag halvårsutdelning AZN 5.01 |
| 2001-08-22 | - | X-dag halvårsutdelning AZN 2.44 |
| 2001-02-21 | - | X-dag halvårsutdelning AZN 4.49 |
| 2000-09-04 | - | X-dag halvårsutdelning AZN 2.1 |
| 2000-03-08 | - | X-dag halvårsutdelning AZN 4.01 |
| 1999-09-06 | - | X-dag halvårsutdelning AZN 1.89 |
| 1999-04-01 | - | Split AZN 1:0.5045 |
| 1997-05-26 | - | Split AZN 1:2 |
| 1993-06-14 | - | Split AZN 1:5 |
| 1987-06-04 | - | Split AZN 1:2 |
Beskrivning
| Land | Storbritannien |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
AstraZeneca has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in over 70 countries to Cheplapharm Arzneimittel GmbH (Cheplapharm).
Financial considerations
Under the terms of the agreement AstraZeneca received a payment of $250m from Cheplapharm. AstraZeneca will receive further non-contingent payments equal to $150m during the first half of 2021. The present value of all payments, totalling $400m, will be reported in AstraZeneca's financial statements within Other Operating Income in the fourth quarter of 2020.
Pursuant to London Stock Exchange listing rule 10.4.1R (notification of class 2 transactions), in 2019 Atacand and Atacand Plus generated product sales of $148m and profit before tax of $89m in the countries covered by the agreement. The gross book value of assets subject to the divestment at 31 December 2019 was $nil. The consideration was and will be paid in cash, and the proceeds used for general corporate purposes.
Atacand
Atacand (candesartan cilexetil) is a selective AT1 subtype angiotensin II receptor antagonist that is indicated for the management of hypertension in adults and children/adolescents, as well as heart failure in adults. Atacand Plus is indicated for the management of hypertension when candesartan or hydrochlorothiazide monotherapy is not sufficiently effective. Atacand was developed in collaboration with Takeda Pharmaceutical Company Limited. Each company held the exclusive rights to the medicine in certain countries; in other countries, Atacand was co-marketed.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the Company on Twitter @AstraZeneca (https://twitter.com/AstraZeneca).
Contacts
For details on how to contact the Investor Relations Team, please click here (https://www.astrazeneca.com/investor-relations.html#Contacts). For Media contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html).